Predictive Genetic Counselling Market Report 2026

The predictive genetic counselling market size has grown rapidly in recent years. It will grow from $4.19 billion in 2025 to $4.87 billion in 2026 at a compound annual growth rate (CAGR) of 16.2%. The growth in the historic period can be attributed to increasing utilization of family history evaluation, expansion of cancer risk screening programs, growing acceptance of genetic testing, improvements in counseling methodologies, rising public awareness of inherited diseases.

The predictive genetic counselling market size is expected to see rapid growth in the next few years. It will grow to $8.79 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to increasing integration of genomics into routine healthcare, rising adoption of virtual counseling platforms, expansion of preventive screening initiatives, growing use of ai-based genetic interpretation, increasing demand for personalized health risk insights. Major trends in the forecast period include increasing demand for online genetic counseling services, rising use of polygenic risk scoring, growing adoption of direct-to-consumer genetic testing, expansion of predictive oncology counseling, enhanced focus on patient education and decision support.

The increasing prevalence of genetic disorders is expected to drive the growth of the predictive genetic counselling market in the coming years. Genetic disorders are conditions caused by changes or defects in an individual’s DNA, affecting growth, development, and overall bodily function. The rise in these disorders is partly due to increasing parental age, as older parental age at conception is linked to a higher likelihood of genetic mutations in offspring. The growing incidence of genetic disorders supports the demand for predictive genetic counselling by increasing the need for risk assessment services that help individuals understand their likelihood of inheriting or passing on such conditions. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based charitable organization, reported that the number of registered cystic fibrosis patients rose to 11,318 in 2023, up from 11,148 in 2022. Therefore, the increasing prevalence of genetic disorders is driving the predictive genetic counselling market.

Key companies in the predictive genetic counselling market are focusing on advanced solutions, such as predictive genetic testing services, to enable early disease risk detection and support informed clinical decision-making. Predictive genetic testing analyzes an individual’s DNA to identify genetic variations linked to a higher risk of developing specific inherited conditions or diseases. For instance, in August 2024, Genetic Technologies Limited, an Australia-based genomics health testing company, launched the geneType Risk Assessment test. This comprehensive multi-risk screening tool evaluates an individual’s likelihood of developing serious conditions, including breast, colorectal, ovarian, and prostate cancers, coronary artery disease, and type 2 diabetes. It combines clinically validated polygenic risk scores with non-genetic factors such as age, family history, and clinical measurements to provide a personalized, actionable risk profile. The test is designed for proactive health management and delivers clear reports with tailored recommendations for preventive care and lifestyle guidance in over 42 countries.

In February 2025, Tempus AI Inc., a US-based provider of AI-enabled precision medicine and diagnostic solutions, acquired Ambry Genetics for USD 600 million. This acquisition gives Tempus AI access to Ambry’s established genetic-testing infrastructure, variant-interpretation expertise, and comprehensive hereditary-risk testing portfolio, enhancing its capabilities in genomic diagnostics while expanding operational scale, clinical-testing reach, and service delivery. Ambry Genetics is a US-based provider of genetic-testing services specializing in hereditary cancer screening, rare-disease testing, and advanced variant interpretation.

Major companies operating in the predictive genetic counselling market are Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN NV, Natera Inc, Myriad Genetics Inc., Fulgent Genetics Inc, Invitae Corporation, 23andMe Holding Co, Color Genomics Inc, deCODE genetics, Centogene NV, Admera Health LLC, Mapmygenome, Exact Sciences Corporation, BGI Group.

North America was the largest region in the predictive genetic counselling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive genetic counselling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the predictive genetic counselling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the predictive genetic counselling market by increasing costs of imported genetic testing platforms, laboratory consumables, diagnostic software tools, and sequencing-related equipment. Diagnostic laboratories and counseling providers in North America and Europe are most affected due to dependence on imported genetic technologies, while Asia-Pacific faces cost escalation in expanding predictive testing services. These tariffs are increasing service delivery costs and slowing infrastructure expansion. However, they are also promoting domestic test kit development, regional laboratory capacity building, and innovation in cost-effective genetic counseling solutions.

The predictive genetic counselling market research report is one of a series of new reports that provides predictive genetic counselling market statistics, including predictive genetic counselling industry global market size, regional shares, competitors with a predictive genetic counselling market share, detailed predictive genetic counselling market segments, market trends and opportunities, and any further data you may need to thrive in the predictive genetic counselling industry. This predictive genetic counselling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Predictive genetic counselling is a process that assesses an individual’s likelihood of developing or transmitting genetic disorders, often before any symptoms appear. It involves analyzing genetic test results, reviewing family history, and explaining potential health implications. The goal is to enable informed healthcare, lifestyle, and reproductive decisions, support early disease prevention, and provide emotional guidance in managing genetic risk information.

The main types of predictive genetic counseling services include risk assessment, carrier testing, predictive testing, and others. Risk assessment services collect personal and family health histories, existing genetic test results, and factors such as ethnicity to estimate an individual’s probability of developing a genetic disorder. These services encompass a variety of predictive tests, including genetic susceptibility tests, predictive diagnostics, and population screening, and are delivered through multiple formats, including in-person consultations and online platforms. They are applied across a range of areas, including consumer genomics, breast and ovarian cancer, cardiovascular screening, diabetes screening and monitoring, colorectal cancer, Parkinson’s or Alzheimer’s disease, urologic and prostate cancer screening, orthopedic and musculoskeletal disorders, and more. End users include hospitals and clinics, diagnostic laboratories, research and academic institutions, among others.

The predictive genetic counselling market includes revenues earned by entities through the pharmacogenomic testing, prenatal testing, newborn screening, and lifestyle or prevention planning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.